A randomized, open-label study of MabThera retreatment on treatment response in patients with active rheumatoid arthritis and inadequate response to anti-TNF therapy.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Aug 2010
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Roche
- 16 Apr 2010 Planned initiation date (Jan 2000) added as reported by Roche record.
- 25 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by Roche record.
- 23 Feb 2010 Status changed from active, no longer recruiting to recruiting as reported by Roche record